Investors

Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system.

Share price (helsinki)

Share price (london)

HALF-YEAR FINANCIAL RESULTS
1 JANUARY – 30 JUNE 2025

Faron Pharmaceuticals announced the Company’s unaudited half-year financial results for 1 January – 30 June 2025 on 27 August 2025. Please review the presentation and the webcast recorded on 27 August 2025.

financial statement 2024

Faron Pharmaceuticals announced the Company’s audited full-year financial results for 1 January to 31 December 2024 on 27 February 2025. Please review the presentation and the webcast recorded on 27 February 2025.

Capital markets day 2024

On 22 October 2024, Faron hosted a Capital Markets Day at the company’s facilities in Turku and on-line. In the event, Juho Jalkanen, CEO of Faron, discussed Faron’s strategy and key focus areas for the coming years. Dr. Kontro shared updated survival data from the ongoing BEXMAB Phase I/II trial and Mr. Hughes presented the results of recently conducted market research in MDS. Dr. Bono provided Faron’s development plan for solid tumors, discussed bexmarilimab’s further potential as first-in-class immune-oncological treatment and introduced the Company’s new Scientific Advisory Board (SAB).

Latest investor presentation

Please review the latest Faron Pharmaceuticals investor presentation in the accompanying presentation. The presentation covers Faron’s strategy, development pipeline, key strengths, and financials.